• Regulatory authorities in Estonia, Latvia and Lithuania grant marketing authorizations for AirFluSal® Forspiro®
• Approval for 50-250 and 50-500µg dosage forms
• AirFluSal Forspiro already launched in four European countries and South Korea

Holzkirchen, November 4, 2014 – Sandoz announces today that the pharmaceutical regulatory authorities in Estonia, Latvia and Lithuania have all granted marketing authorizations for AirFluSal® Forspiro®, an innovative new inhaler for patients with asthma and/or chronic obstructive pulmonary disease (COPD). …